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Abstract The role of the T helper (Th)17 pathway has been
clearly demonstrated in the onset and progression of autoim-
mune diseases, where interleukin (IL)-23 is a key molecule in
maintaining the response mediated by Th17 cells. As a conse-
quence, recent strategies based on blocking the interaction be-
tween IL-23 and its receptor (IL-23R), for example the anti-p19
antibody tildrakizumab, have been developed to regulate the
Th17 pathway from the initial stages of the disease. Here, a
soluble (s)IL-23R cDNA was cloned in expression plasmids
and viral vectors. The clinical efficacy of sIL-23R was
evaluated in myelin oligodendrocyte glycoprotein-induced ex-
perimental autoimmune encephalomyelitis mice intravenously
injected with a single dose of adeno-associated virus AAV8–
sIL-23R vectors. Cytokine secretion was determined by multi-
plex assay, while histopathological analysis of the central ner-
vous system was performed to study demyelination, inflamma-
tory infiltration, and microglia and astroglia activation. We ob-
served that administration of adeno-associated vector 8
encoding sIL-23R was associated with a significant disease im-
provement, including delay in the onset of the clinical signs;
slower progress of the disease; interference with IL-23-
mediated signal transducer and activator of transcription re-
sponse by inhibiting of signal transducer and activator of tran-
scription 3 phosphorylation; reduced demyelination and infiltra-
tion in the central nervous system; and lower astrocyte and
microglia activation. Our results suggest that the use of vectors
carrying sIL-23R to block the IL-23/IL-23R interaction may be
a new therapeutic strategy for the treatment ofmultiple sclerosis.
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Introduction
Multiple sclerosis (MS) is a chronic neurodegenerative and
demyelinating autoimmune disease that affects an estimated
2.5 million people worldwide. Unfortunately, despite efforts
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to develop new therapies, there is no curative treatment, and
long-term prognosis remains poor for patients.
Recently, the role of the T helper (Th)17 pathway has been
demonstrated in the development ofMS,where interleukin (IL)-
23 is a key molecule in maintaining the response mediated by
Th17 cells [1–3]. Compared with healthy controls, 40% of pa-
tients with MS have an increased number of Th17 cells in the
peripheral blood [4]. In addition, patients in the acute phase of
the disease had 3.5 times more Th17 cells than patients in re-
mission. Furthermore, patients with MS also had more Th17
cells in the cerebrospinal fluid than patients with noninflamma-
tory neurological diseases, suggesting their recruitment or en-
richment to sites of inflammation in MS [5]. It is noteworthy
that adoptive transfer of myelin oligodendrocyte glycoprotein
(MOG)-specific Th17 cells reproduces experimental autoim-
mune encephalomyelitis (EAE), an experimental model of
MS. Autoantigen-specific Th17 cells cross the blood–brain bar-
rier and infiltrate the central nervous system (CNS) before the
clinical signs of EAE [6]. Furthermore, the administration of
anti-IL-17 and anti-IL-23 monoclonal antibodies in an EAE
model reduced the severity of the disease [7–10]. Recent data
suggest that IL-23 is not only necessary to stabilize the popula-
tion of Th17 cells in the secondary lymphoid tissue, but also to
maintain a pathogenic Th17 population at the site of inflamma-
tion [11]. Although IL-23p19-deficient mice were resistant to
EAE [1], IL-17-deficient mice developed the disease [12, 13].
Thus, inhibition of IL-23 may be a strategy to control the de-
regulation of the Th17 pathway during the initial stages of the
disease and the evolution of the inflammatory autoimmune
response.
Different immunosuppressors have been used for MS in
animals and in human clinical trials. For example,
ustekinumab is a monoclonal antibody against p40, the com-
mon subunit of IL-12 and IL-23, and is effective against pso-
riasis and Crohn's disease [14, 15] but has not succeeded in
MS [16], possibly because it is directed against the p40 do-
main and therefore not only inhibits IL-23, but also IL-12. As
an alternative, specific biological treatments for the p19 sub-
unit of the IL-23 heterodimer have been developed.
Interestingly, a recent study performed by Guo et al. [17]
shows that the continuous administration of soluble recombi-
nant IL-23 receptor (IL-23R) cytokine-binding homology re-
gion blocks the interaction between IL-23 and the IL-23R and
ameliorates the clinical signs of EAE, paving the way for
similar strategies, such as secukinumab (anti-IL-17A anti-
body), to treat Th17-mediated autoimmune diseases, includ-
ing MS [18].
For the purpose of finding new strategies in the fight
against MS based on the control of the Th17 inflammatory
axis, here we report that a single administration of adeno-
associated virus (AAV) vectors carrying the coding sequence
of soluble IL-23R (sIL-23R) delays the onset of the clinical
signs, slows the progress of the disease, and reduces the
inflammatory infiltration and demyelination in the CNS in a
MOG-induced EAE mouse model.
Methods
Viral Vector Generation, Production, and Purification
AAV8 and first-generation Adenovirus 5 (Ad5) vectors were
produced, purified, and manipulated at biosafety level 2 facil-
ities at the Universitat Autònoma Barcelona, Spain. Briefly,
for the production of Ad5 vectors, PacI-linearized plasmids (6
μg) containing the adenovirus genomes, as well as green fluo-
rescent protein (GFP), mouse IL-23R, sIL-23R, or null se-
quences, were transfected into 1 × 106 HEK293 cells, and
the virus was recovered 8 to 10 days post-transfection. Then,
viruses were sequentially amplified until the infection of 4 ×
108 HEK293 cells. Viral particles were measured by absor-
bance of disrupted virions at 260 nmwhere one OD equals 1 ×
1012 particles/ml, while infective particles were measured by
an endpoint dilution assay that counted the number of hexon-
producing cells in triplicate [19, 20]. AAV8 vectors were gen-
erated using the triple-transfection system in HEK293 cells.
After 48 h, AAV vectors were harvested, treated with
benzonase, purified in an iodixanol gradient, and titrated using
the PicoGreen® system [21]. In all cases, transgene expres-
sion was driven by a cytomegalovirus promoter.
Immunodetection and Immunoprecipitation of sIL-23R
HEK293 and Jurkat cells were sonicated and homogenized in
lysis buffer [50 mM Tris-Cl (pH 7.4), 150 mM NaCl, 1 mM
ethylenediamine tetraacetic acid, 1% NP-40, 0.25% sodium
deoxycholate and Protease Inhibitor Cocktail Set I (Millipore,
Billerica, MA, USA)]. Total protein concentration was deter-
mined using the Pierce BCA Protein Assay (Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufac-
turer’s instructions and with bovine serum albumin as the stan-
dard. Sample absorbance at 562 nm was measured using a
NanoDrop 1000 UV/Vis spectrophotometer (Thermo Fisher
Scientific). Protein extracts (15–25 μg/sample) were loaded on-
to denaturing acrylamide gels and then electrotransferred to
polyvinylidene fluoride membranes (Amersham, Little
Chalfont, UK). Primary antibodies were incubated in the pres-
ence of 5% (w/v) skimmed milk combined with Western blot-
ting detection reagent (ECL Plus; Amersham). Band pixel in-
tensities were quantified using Image J (National Institutes of
Health, Bethesda,MD,USA) and normalized by antiactin levels
in each lane. Anti-IL-23R (AF1686; R&D Systems,
Minneapolis, MN, USA) and secondary antibody rabbit
antigoat Ig horseradish peroxidase (P0160; Dako, Glostrup,
Denmark) were used at a dilution of 1:2000 and 1:5000, respec-
tively. Antioctaprobe (Sc-807; Santa Cruz Biotechnology, Santa
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Cruz, CA, USA) and secondary antibody swine antirabbit Ig
horseradish peroxidase (P0399; Dako) were used at a dilution
of 1:500 and 1:5000, respectively.
HEK293 cells transfected with the GST–sIL-23R or the sIL-
23R plasmids were collected and proteins (extracted as de-
scribed previously) were incubated with glutathione-sepharose
4B (GE Healthcare Life Sciences, Uppsala, Sweden) at 4°C for
2 h. Samples were rinsed 3 times, and eluted with glutathione-
eluted buffer [50 mMTris-HCl, 0.1 mM ethylene glycol-bis (β-
animoethyl ether)-N,N,N',N'-tetraacetic acid, 0.275 M saccha-
rose, 0.1% β-mercaptoethanol, 40 mM reduced glutathione, pH
8.0] for 25 min with agitation. Finally, samples were incubated
at room temperature for 5 min, and supernatants were trans-
ferred to fresh tubes and stored at –80°C until use.
Western Analysis
sIL-23R was produced in 150-mm plates (HEK-293 cells in
Dulbecco’s modified eagle medium + 1% fetal bovine serum)
and infected with Ad5/sIL-23R or control Ad5/GFP at a multi-
plicity of infection of 10. Cells were harvested 28 h postinfec-
tion, lysed, and crude lysates stored at –80°C until use.
Splenocytes (2 × 106 cells/ml, 3 ml of final volume) were cul-
tured in 6-well plates with sIL-23R-conditioned medium. One h
after seeding, IL-23 (final concentration of 10 ng/ml) was added
to cells for 5 min. In competition experiments, IL-23 was pre-
viously co-incubated with sIL-23R-conditioned medium for 1
h. Splenocytes were harvested, medium discarded by centrifu-
gation, and cells resuspended in 100 μl lysis buffer (25 mM
Tris-HCl at pH 7.6, 210 mM NaCl, 1 mM ethylenediaminetet-
raacetic acid, 1% Nonidet P40, 0.1% sodium dodecyl sulfate)
containing a mixture of protease and phosphatase inhibitors
(Millipore, Darmstadt, Germany). Antibodies against total sig-
nal transducer and activator of transcription (STAT)3, and
Y705-phosphoryl STAT3 (pY705-STAT3), were from Cell
Signaling Technology (Danvers, MA, USA), and antibody
against actin from Sigma Chemicals (St. Louis, MO, USA).
Cell debris was removed by centrifugation. Protein (40 μg)
was loaded onto 10% (wt/vol) sodium dodecyl sulfate poly-
acrylamide electrophoresis gels. The separated proteins were
transferred to polyvinylidene fluoride membranes (Millipore,
Darmstadt, Germany). The membranes were incubated with
primary antibody at 4°C overnight, followed by incubation with
secondary antibody for 1 h at room temperature. Band intensity
was quantified using ImageJ.
β-Galactosidase Analysis
To facilitate quantitation of transgene expression an AAV8 vec-
tor expressing β-galactosidase was used. AAV8 serotype was
selected owing to its high efficiency in infecting several organs,
including liver and skeletal muscle, after intravenous adminis-
tration, and also because AAV8-mediated transgene expression
is stable for years. Animals injected with AAV8–β-galactosi-
dase [5 × 1011 viral genomes (vg)/mouse; n = 4 or 5 per group]
were euthanized 3 weeks after AAV administration, so all ani-
mals were expressing β-galactosidase the same period of time.
In vivo, β-galactosidase expression was quantified using the
Galacto-Light Plus System (Applied Biosystems, Foster City,
CA, USA) and a luminometer (Monolight 2010; Analytical
Luminescence Laboratory, USA) according to the manufac-
turers’ recommendations. β-Galactosidase activity was normal-
ized to total protein concentration (protein assay reagent; Bio-
Rad Laboratories, Hercules, CA, USA).
Animals
C57BL/6J 8–10-week-old female mice purchased from
Harlan Laboratories (Milan, Italy) were used. Mice were
housed under standard light- and climate-controlled condi-
tions, and standard chow and water were provided ad libitum.
Ethics, Consent, and Permissions
All experiments were performed in strict accordance with
European Union and governmental regulations (Generalitat
de Catalunya Decret 214/97 30 July). The Ethics Committee
on Animal Experimentation of the Vall d’Hebron Research
Institute approved all procedures described in this study (pro-
tocol number: CEEA 40/10/11-DAAM 5614; CEEA 81/11-
DAAM 6364).
In Vivo Administration of AAV Vectors
In order to define an optimal time of vector administration, a
preliminary in vivo experiment was performed before and after
EAE induction. To facilitate quantitation of transgene expression
an AAV8 vector expressing β-galactosidase was used. AAV8
serotype was selected owing to its high efficiency in infecting
several organs, including liver and skeletal muscle, after intrave-
nous administration, and also becauseAAV8-mediated transgene
expression is stable for years. AAV8–β-galactosidase vectors (5
× 1011 vg/mouse; n = 4 or 5 per group) were injected at days –6,
–2, +5, and +9 postimmunization (p.i.), and euthanized 3 weeks
after AAVadministration; therefore, all animals were expressing
β-galactosidase in the same period of time.
To analyze the effect of sIL-23R expression in EAE out-
come, 18 days before EAE induction, a single dose (9 × 1010–
5 × 1011 vg/mouse) of AAV8 vectors (sIL-23R or null) was
administered by intravenous injection through the lateral tail
vein.
EAE Induction and Clinical Follow-Up
Anesthetized mice were immunized by subcutaneous injec-
tions of 100 μl phosphate-buffered saline (PBS) containing
Amelioration of EAE by Soluble IL-23 Receptor 1097
100 μg MOG peptide 40–55 (MOG40–55) (Proteomics
Section, Universitat Pompeu Fabra, Barcelona, Spain)
emulsified in 100 μl Complete Freund's Adjuvant (Sigma
Chemicals) containing 4 mg/ml Mycobacterium
tuberculosis H37RA (Difco Laboratories, Franklin Lakes,
NJ, USA). At days 0 and 2 p.i., mice were intravenously
injected with 250 ng pertussis toxin (Sigma Chemicals).
Two animals per group were used as control mice (sham
immunization), which were immunized in the same manner
using PBS in the absence of the peptide. Mice were
weighed and examined daily for neurological signs using
the following criteria: 0 = no clinical signs; 0.5 = partial
loss of tail tonus for 2 consecutive days; 1 = paralysis of
whole tail; 2 = mild paraparesis of one or both hindlimbs;
2.5 = severe paraparesis or paraplegia; 3 = mild
tetraparesis; 4 = tetraparesis (severe in hindlimbs); 4.5 =
severe tetraparesis 5 = tetraplegia; 6 = death (modified from
[22]). All data presented are in accordance with the guide-
lines suggested for EAE publication [23]. Weight loss was
calculated as the percentage change in daily weight com-
pared with the initial weight on the day of immunization.
Score 5 and weight loss > 30% were defined as endpoint
criteria to minimize suffering and guarantee animal welfare.
In the different experiments, incidence of EAE in the EAE
control untreated group (n = 8-13 per group in each exper-
iment) was 100%.
Splenocyte Proliferative Assay and Cytokine Production
Five mice per group were used to perform immunolog-
ical assays. Splenocytes were removed from euthanized
mice at day 14 p.i. and seeded at 2 × 105 cells/well in a
96-well plates in Iscove’s modified Dulbecco’s medium
(PAA Laboratories GmbH, Pasching, Austria) supple-
mented with 10% HyClone FetalCloneI (Thermo Fisher
Scientific), 50 μmol/l 2-mercaptoethanol (Sigma
Chemicals), 2 mmol/l L-glutamine, 50 U/ml penicillin,
and 50 mg/ml streptomycin, all obtained from Gibco
(Paisley, UK), and 5 μg/ml MOG40–55 or 5 μg/ml phy-
tohemagglutinin (PHA) (Sigma Chemicals). Cells cul-
tured without any stimulus were used as controls.
After 48 h, the supernatants (50 μl/well) were harvested
and stored at –80°C to further assess cytokine release.
Then, the cell cultures were incubated in the presence
of 1 μCi/well [3H]-thymidine (Perkin Elmer, Waltham,
MA, USA) under the same conditions for an additional
18 h, and the levels of incorporated radioactivity were
measured using a β-scintillation counter (Wallac, Turku,
Finland). Five replicates for each mouse and condition were
performed. The stimulation index was calculated by dividing
the arithmetic mean of counts per minute from stimulated
cultures by the arithmetic mean of counts per minute from
control cultures.
Cytokine secretion was determined both in the supernatants
of MOG40–55-stimulated splenocytes and in the serum of 5
mice per group by flow cytometry using the MILLIPLEX
MAP Mouse Th17 Magnetic Bead Panel-Immunology
Multiplex Assay (Merck-Millipore, Darmstadt, Germany), ac-
cording to the manufacturer’s instructions. Quantification was
performed using Luminex MagPix and the xPONENT 4.2
software.
Histopathological Studies
At day 14 p.i., 5 mice from each group were euthanized
and brains and spinal cords were collected and fixed in
4% paraformaldehyde at 4°C for 48 h. Samples were
washed with PBS and incubated in 30% saccharose at
4°C for cryoprotection. Then, samples were embedded
in OCT, frozen on dry ice, and cryosectioned into
20-μm slices. To determine the inflammatory infiltrates
hematoxylin and eosin staining was performed, and de-
myelination was assessed by Klüver–Barrera staining.
Cell infiltration was evaluated using hematoxylin and eo-
sin staining according to the following criteria: 0 = no
lesion; 1 = cellular infiltration only in the meninges; 2 =
very discrete and superficial infiltrates in the parenchy-
ma; 3 = moderate infiltrate (< 25%) in the white matter; 4
= severe infiltrates (< 50%) in the white matter; 5 = more
severe inf i l t ra tes (> 50%) in the whi te mat te r.
Demyelination (Klüver–Barrera staining) was scored as
follows: 0 = no demyelination; 1 = little demyelination,
only around infiltrates, and involving < 25% of the white
matter; 2 = demyelination involving < 50% of the white
matter; 3 = diffuse and widespread demyelination involv-
ing > 50% of the white matter.
Microglia and astroglia activation was analyzed using a
Leica TCS SP2 confocal microscope by quantifying the inte-
grated fluorescence intensity of specific markers Iba1 (Wako-
019-19741; WAKO, Osaka, Japan) for microglia, and GFAP
(Sigma-G3893; Sigma Chemicals) for astroglia using the
Metamorph 5.0r1 program.
Statistical Analysis
Data are expressed as the mean ± SEM values unless other-
wise stated. Statistical analysis was performed using G-Stat
version 2.0 and Prism 5.04 software (GraphPad Inc., La Jolla,
CA, USA). Except for the results presented in Figs 3B and 4B,
statistical significance between individual groups was deter-
mined by nonparametric Mann–Whitney or Kruskal–Wallis
tests. Analysis of variance plus post-hoc Tukey’s honest sig-
nificant difference test was used for the results shown in
Fig. 3B, while a t-test (unpaired, 2-tailed) was used for the
results shown in Fig. 4B. In all the statistical analyses, p < 0.05
was considered significant.
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Fig. 1 (A) Comparison of the
human and murine interleukin-23
receptor (IL-23R) genomic struc-
tures and the design scheme based
on the soluble human (s)IL-23R
isoform. (B) Amino-acid se-
quence of murine IL-23R and de-
signed murine sIL-23R. Amino
acids in blue were added by anal-
ogy with soluble human IL-23R
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Results
Design and Cloning of Murine sIL-23R
Human sIL-23R may be naturally produced by alternative
splicing to generate a sIL-23R isoform [24]. However, the
soluble form of the murine IL-23R (NCBI GenBank
NM_144548.1) has not yet been described. We designed the
equivalent mouse sIL-23R by mimicking the alternative splic-
ing of the human sIL-23R that essentially eliminates exons 10
and 12. First, by analogy to human IL-23R4, we selected the
sequence between the initiation ATG codon of exon 2 and the
beginning of exon 10, just before the sequence corresponding
to the transmembrane region (Fig. 1A). Furthermore, since the
C-terminus of human sIL-23R includes a set of amino acids
(LKEGSYC) belonging to exon 12, the same amino-acid se-
quence was also added to murine sIL-23R in case it was im-
portant for the function or stability of the protein (Fig. 1B).
According to protein prediction programs, the designed sIL-
23R gene should be secreted extracellularly. Murine sIL-23R
was generated by DNA synthesis, cloned into adenovirus vec-
tor (Ad)5 and AAV8 genomes, and its identity was confirmed
by sequencing. Before in vivo experiment, AAV vector infec-
tivity and AAV-mediated transgene expression were verified
by in vitro infection and further mRNA analysis (data not
shown).
Cellular Distribution of IL-23R and sIL-23R
HEK293 cells were infected with Ad5–IL-23R, Ad5–FLAG–
IL-23R, Ad5–sIL-23R, and Ad5–FLAG–sIL-23R with a mul-
tiplicity of infection of 2 in order to analyze the cellular dis-
tribution of IL-23R and sIL-23R. Two days after infection, the
cells were fixed and analyzed by immunofluorescence with
antibodies against IL-23R. Confocal microscopy showed that
IL-23R was located in the membrane (Fig. 2A). These results
were reproduced using the anti-FLAG and antioctaprobe an-
tibodies (data not shown). In contrast, sIL-23R receptor was
Fig. 2 (A) Cellular distribution of interleukin-23 receptor (IL-23R) and
soluble (s)IL-23R. Immunofluorescence with anti-IL-23R antibody
(green). Nuclei are stained with 4,6-diamidino-2-phenylindole (DAPI;
blue). Representative photos from 3 independent experiments (n = 5wells
each) where HEK293 cells were infected with adenovirus (Ad)5-IL-23R
or Ad5–sIL-23R. (B) sIL-23R is produced and secreted into the
extracellular medium. Western blotting with primary antioctaprobe anti-
body after immunoprecipitation. Samples: extracellular medium of Jurkat
cells infected with Ad5–green fluorescent protein (control); Ad5–FLAG–
IL-23R (IL-23R) or Ad5–FLAG–sIL-23R (sIL-23R). Experiment was
performed 3 times, and representative results selected L = protein extract
from cell lysates; M = protein extract from cell media
Fig. 3 Soluble interleukin-23 receptor (sIL-23R)/interleukin-23 (IL-23)
binding inhibits phosphorylation of signal transducer and activator of
transcription 3 (STAT3) caused by interleukin (IL)-23. Splenocytes were
incubatedwith 10 ng/ml of IL-23 for 5min.When applied, IL-23 and sIL-
23R were co-incubated for 1 h prior addition to cell culture media. (A)
Representative Western blot for STAT3 and phosphorylated (p)STAT3.
(B) Quantification of the ratio pSTAT3/STAT3 from 4 independent ex-
periments (n = 2 or 3 per experiment). **p<0.01
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not found in the cell membrane but was diffuse in the cyto-
plasm (Fig. 2A).
To study whether sIL-23R was secreted or stayed within
the cytoplasm, we measured the presence of sIL-23R in the
culture medium. During our initial experiments we did not
succeed in detecting murine sIL-23R using commercial anti-
IL-23R antibodies, and so a new set of viral vectors, including
either a FLAG-tag or a GST-tag at the N-terminus of the con-
struct were generated. In addition, owing to the higher effi-
ciency of Ad5 vectors compared with AAV8 vectors, to infect
cells in vitro, we used Ad5 vectors for in vitro assays. To
confirm the secretion of sIL-23R into the extracellular medi-
um, Jurkat cells were infected with Ad5–sIL23R, and 2 days
later, supernatants were concentrated and immunoprecipitated
with anti-FLAG. As seen in Figure 2B, Western blotting with
an antioctaprobe antibody showed a band of the expected size
in protein extracts from cell media only when the sIL-23R–
FLAG construct was used, while no band was detected when
using the GFP or the transmembrane IL-23R controls.
sIL-23R Inhibits IL-23R Signaling
Yu and Gallagher [25] have reported that the soluble variant of
the human IL-23R binds IL-23 in solution (and not IL-12).
This sIL-23R/IL-23 binding inhibits phosphorylation of
STAT3 caused by IL-23 and subsequently, modulates the
Th17 cells by inhibiting the production of the Th17-
associated cytokines IL-17A and IL-17F. In order to know
whether murine sIL-23R antagonize IL-23-mediated STAT3
response, splenocytes incubated with IL-23 and IL-23/sIL-
23R were analyzed. As seen in Figure 3, co-incubation of
IL-23 and sIL-23R does not alter levels of total STAT3 but
abolishes STAT3 phosphorylation (p > 0.01), confirming the
therapeutic potential of sIL-23R to functionally antagonize IL-
23, and therefore to modulate the Th17 pathway.
In vivo Administration of sIL-23R EAE Mice
In order to define an optimal time of vector administration,
AAV8–β-galactosidase vectors (5 × 1011 vg/mouse; n = 4 or 5
per group) were injected at days –6, –2, +5, and +9 p.i., and
euthanized 3 weeks after AAVadministration. Interestingly, as
seen in Figure 4, AAV8-mediated β-galactosidase expression
was much higher when administering the vectors before EAE
induction, while transgene expression was severely reduced
when administering after EAE induction (between 3–4-fold
and 6–8-fold higher than those observed at day +5 and day
+9, respectively). This effect was more evident when vectors
were administered 2 or 3 weeks before EAE induction (data
not shown). Therefore, in this model for EAE only the pre-
ventive approach but not the therapeutic approach seems fea-
sible, unless other strategies such as promoters that can be
regulated can be used.
To analyze the effect of sIL-23R expression in EAE out-
come, a dose of 5 1011 vg of AAV8–sIL-23R or AAV8-null
was administered intravenously to each animal at day 18
preimmunization. As seen in Figure 5A, the animals treated
with AAV8–sIL-23R showed a significant improvement in the
clinical signs of the disease compared with those treated with
the null vector. Moreover, clinical improvement was stable
and sustained over time until the end of the experiment, with
a mean clinical score on the last day of 4.69 ± 0.84 in the
control group and of 2.71 ± 1.70 in the sIL-23R group (p =
0.012). In addition, the cumulative clinical score was 39.8 ±
28.2 for AAV8–sIL-23R-treated animals, while for the AAV8-
null group it was 84.4 ± 12.9 (p = 0.003). Furthermore a trend
Fig. 4 Adeno-associated virus AAV8-mediated β-galactosidase (βGal)
expression before (day –6; day –2) and after (day +5; day +9) the induc-
tion of experimental autoimmune encephalomyelitis (EAE). Animals
were untreated (EAE), or treated with 5 × 1011 viral genomes of AAV8-
null or AAV8-βGal vectors. EAE induction is considered day +0. βGal
expression was measured by relative light units (RLU) per μg of protein
Amelioration of EAE by Soluble IL-23 Receptor 1101
toward a delay in disease onset was observed: 12.7 ± 2.6 for
sIL-23R-treated mice, and 10.9 ± 1.4 for control-treated mice
(p = 0.060). It is broadly described that EAE disease is asso-
ciated with a body weight loss that may plateau during the
chronic stage. We also observed that animals treated with the
null virus had a more pronounced tendency towards weight
loss than the group treated with sIL-23R during the experi-
ment (p = 0.060; Fig. 5B).
Interestingly, the effect observed was dose-dependent,
since lower doses (9 × 1010 vg/mouse) of the AAV8–sIL-
23R vector only slightly ameliorated clinical signs without
reaching statistical significance (mean cumulative score of
55.2 ± 19.2 for AAV8–sIL-23R-treated animals and 70.1 ±
19.3 for AAV8-null–treated animals; Fig. 5C).
Immunological Analysis of Mice Treated
with AAV8-sIL-23R
Five mice for each treatment condition were euthanized at 14
days p.i. for immunological and histopathological studies.
Splenocytes from these mice were cultured in the presence
of the MOG40–55 peptide or PHA for cell proliferation assays.
Despite the differences observed in the clinical score, no dif-
ferences were observed in the polyclonal proliferation to PHA
of splenocytes between the null and sIL-23R groups (stimula-
tion index of 44.8 ± 8.8 and 31.3 ± 3.7, respectively; p =
0.152), or the antigen-specific proliferation (stimulation index
of 25.3 ± 2.5 and 28.1 ± 3.0, respectively; p = 0.457) (data not
shown).
Next, the cytokines secreted into the culture medium of
MOG40–55-stimulated splenocytes were analyzed using the
Luminex system Magpix. The analysis showed a statistically
significant difference in the concentration of interferon
(IFN)-γ (null: 1765.9 ± 1146.1 pg/ml; sIL23R: 5691.3 ±
2639.3 pg/ml; p = 0.016), as well as a trend toward higher
production of granulocyte macrophage colony-stimulating
factor (null: 146.2 ± 106.6 pg/ml; sIL23R: 337.4 ± 188.0 pg/
ml; p = 0.083), which did not reach statistical significance. For
other cytokines (IL-2, IL-4, IL-5, IL-6, IL-10, IL-17A, IL-22),
no differences were detected between the 2 groups. IL-21 was
below the detection limit of the kit in all samples. In addition,
cytokine concentrations in the serumwere also analyzed. Only
IFN-γ, IL-6, IL-5, and IL-22 reached the detection limit of the
assay. However, none of these cytokines showed differences
in serum concentration between the treated and control
groups.
Histopathological Analysis of the CNS
A histopathological study was performed to assess the degree of
inflammation and demyelination of the spinal cords of the treated
animals. Of note, the histopathology of sIL-23R-treated mice
was consistent with the observed clinical outcome. In the null-
Fig. 5 Administration of adeno-associated virus AAV8–soluble
interleukin-23 receptor (sIL-23R) significantly reduces the clinical course
of experimental autoimmune encephalomyelitis (EAE). (A) Mean daily
clinical score for each group. Bars represent the SEM. The AAV8–sIL-
23R group shows a statistically significant improvement in the clinical
course of the disease compared with the control group treated with
AAV8-null (p = 0.003). (B) Average daily weight change relative to initial
weights on the day of EAE induction. Bars represent the SEM. Animals
immunized with myelin oligodendrocytes glycoprotein (MOG) peptide
40–55 (MOG40–55) and treated with 5 × 10
11 viral genome (vg)/mouse of
AAV8–sIL-23R or AAV8-null (n = 8–13). (C) Lower dose of AAV8–sIL-
23R did not improve the clinical course of EAE. The graph represents the
mean daily clinical evaluation for each group. Bars represent the SEM.
Animals immunized with MOG40–55 and treated with 9 × 10
10 vg/mouse
of AAV8–sIL-23R or AAV8-null (n = 8–11). ***p<0.001.
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treated mice, demyelination and abundant inflammatory infil-
trates (mainly composed of lymphocytes andmacrophages) were
observed in the white matter of the spinal cord. In contrast, in
sIL-23R-treated mice, the inflammatory infiltrate was much
more discrete and no demyelination was observed at day 14
p.i. (Fig. 6A, B). In agreement with this, microglial activation
in sIL-23R-treated mice was similar than in sham-immunized
mice, and astroglial activation was significantly lower than that
observed in null-treated animals. For microglia activation, mean
integrated fluorescence intensity (relative units) in null-treated
mice was 1.6 × 1012 ± 9.3 × 1011 and in sIL-23R-treated mice
it was 0.3 × 1012 ± 2.5 × 1011 (p = 0.03; Fig. 7A, C); and for
astroglial activation mean integrated fluorescence intensity (rela-
tive units) in null-treated mice was 7.4 × 1011 ± 1.8 × 1011 and in
sIL-23R-treated mice it was 2.1 × 1011 ± 7.8 × 1010 (p = 0.01;
Fig. 7B, D).
Discussion
MS is a neurodegenerative disease in which the Th17 immune
response has a relevant role in maintaining and amplifying the
autoreactive T lymphocytes against myelin, which eventually
leads to demyelination in the CNS and severe neurological
disability. Recent reports demonstrate that the activity of IL-
23 is key in expanding and maintaining the Th17 cell popula-
tion [26–29]. Therefore, blocking the IL-23/IL-23R interac-
tion may inhibit the IL-23R-mediated signaling cascade and
thus may have a therapeutic effect either at the initiation phase
or during progression of disease.
It has been described that a therapy based on blocking IL-
23 signaling by anti-p19 monoclonal antibodies prevented the
induction of EAE and reversed the disease once established.
Thus, Chen et al. [7] compared the anti-p40 therapy with anti-
p19 therapy, concluding that although both approaches pro-
vided resistance to autoimmune inflammation, the first caused
numerous side effects owing to the inhibition of both Th1 and
Th17 pathways. Unfortunately, repeated administration of
such biologicals, as the anti-α4 integrin antibody
(natalizumab), appears to induce the formation of neutralizing
antibodies against them with consequent loss of efficiency
[30, 31]. To avoid these problems, Guo et al. [17] adminis-
tered the soluble recombinant IL-23R cytokine-binding ho-
mology region to block the interaction between IL-23 and
IL-23R, observing that their continuous administration signif-
icantly ameliorated clinical signs in the EAE model. In order
to avoid continuous administration of the therapeutic mole-
cule (either exogenous antibodies or recombinant IL-23R)
we decided to study the therapeutic potential of an alternative
approach based on the single administration of AAV vectors
Fig. 6 Inflammation [hematoxylin and eosin (HE)] and demyelination
[Klüver–Barrera (KB)] in the spinal cord at day 14 postimmunization. (A)
Representative sections (n = 5 mice per group). In HE staining arrows
indicate inflammatory infiltrates. In KB staining arrows indicate areas of
demyelination. (B) Inflammatory and demyelination score for null and
soluble interleukin-23 receptor (sIL-23R) groups NULL = spinal cord of
adeno-associated virus AAV8-null treated myelin oligodendrocytes gly-
coprotein (MOG) peptide 40–55 (MOG40–55)-immunized mice (n = 5);
sIL-23R = spinal cord of AAV8–sIL-23R-treated MOG40–55-immunized
mice (n = 5)
Amelioration of EAE by Soluble IL-23 Receptor 1103
carrying sIL-23R. This approach would avoid continuous ad-
ministration of the therapeutic molecule, while still selectively
inhibiting the effects of IL-23 and thereby would specifically
immunomodulate the Th17 pathway.
To this end, we designed the sIL-23R mouse gene de novo,
based on a sIL-23R isoform described previously [24], and
then generated AAV vectors carrying either the IL-23R or sIL-
23R genes. Cells infected with the adenovirus vectors pro-
duced and secreted sIL-23R to the extracellular medium.
Moreover, in infected cells, IL-23R was located at the cell
membrane, whereas sIL-23R was observed in the cytoplasm.
Intravenous administration of AAV8–sIL-23R was associ-
ated with a delay in the onset of the first clinical signs, as well
as a significant clinical improvement until the end of the ex-
periment. Moreover, the variation in body weight was consis-
tent with the clinical effect since EAE generally correlates
with weight loss [32], and it was lower in the sIL-23R-
treated mice than in the control-treated mice. Similarly, histo-
pathological findings were also in accordance with the clinical
improvement observed. Thus, in the spinal cord of sIL-23R-
treated mice, reduced demyelination and the inflammatory
component was observed. At the same time, both the astrocyte
response and microglia activation were significantly lower in
the treated animals, and similar to the control group immu-
nized with saline that did not develop the disease. These re-
sults are in agreement with those reported by Guo et al [17].
Fig. 7 Representative pictures of (A) microglia and (B) astroglia activa-
tion in the spinal cord at day 14 postimmunization (n = 5 mice per group).
Values of integrated fluorescence intensity following immunohistochem-
istry with specific markers (C) Iba1 (microglia) and (D) glial fibrillary
acidic protein (astroglia). Values of integrated fluorescence intensity were
determined in 5 mice per group, 12 slices per mouse, and 3 fields per slice
(40× magnification) Sham = spinal cord of mice immunized without
antigen; NULL = spinal cord of adeno-associated virus AAV8-null treat-
ed myelin oligodendrocytes glycoprotein (MOG) peptide 40–55
(MOG40–55)-immunized mice; sIL-23R: spinal cord of AAV8–soluble
interleukin-23 receptor (sIL-23R)-treated MOG40–55-immunized mice.
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Of note, since intravenous administration of AAV8 vectors at
the indicated doses infect efficiently liver and skeletal muscle
but not CNS [33, 34], the clinical effects observedmust be due
to systemic production of sIL-23R, thus hindering local high
levels of sIL-23R being reached in the brain.
Interestingly, Yu and Gallagher [25] showed that, in vitro,
human sIL-23R modulates the Th17 cells by inhibiting the
phosphorylation of STAT3 caused by IL-23. Similarly, our
studies also show that sIL-23R inhibits the phosphorylation
of STAT3, highlighting the therapeutic potential of sIL-23R to
antagonize IL-23-mediated STAT3 response.
However, when analyzing the medium of cultured
splenocytes frommice treated with AAV8–sIL-23R, we found
that only the levels of IFN-γ were statistically significantly
different (3 times higher) than those observed in control-
treated animals. This is consistent with data reported by other
authors demonstrating that increased IFN-γ is associated with
a better clinical outcome in EAE mice. In fact, IFN-γ is de-
scribed as a potent negative regulator of the immune responses
mediated by the IL-23/IL-17 axis that strongly inhibits the
development of Th17 cells [35, 36]. Moreover, it has been
observed that administration of anti-IFN-γ causes exacerba-
tion of EAE in mice, while administration of exogenous
IFN-γ in mice generated a protective effect against EAE
[37–39]. In addition, IFN-γ-deficient and IFN-γ receptor-de-
ficient mice show a more severe EAE [40, 41]. Therefore, the
apparent clinical improvement of sIL-23R-treated mice
matches the significant increase in IFN-γ production.
However, this increase in IFN-γ was not accompanied by a
significant decrease in the concentration of proinflammatory
Th17 cytokines, such as IL-22 or IL-17A. In fact, even though
a slight increase in granulocyte macrophage colony-
stimulating factor levels was observed, no changes were de-
tected in the pattern of the regulatory or anti-inflammatory
cytokines, such as IL-10 and IL-4. Unfortunately, these results
do not clarify the mechanism of action of this approach, al-
though this will be extensively studied in future experiments,
together with flow cytometric characterization of circulating
and intra-CNS inflammatory cells.
Recently, there has been a major concern regarding the
occurrence of serious side effects in current experimental
treatments for MS [42, 43]. There have been > 200 cases of
progressive multifocal leukoencephalopathy in patients treat-
ed with natalizumab (approximately 1–11/1000 cases, de-
pending on other risk factors and drug exposure time) [44].
However, no studies on the side effects associated with long-
term specific blockage of the IL-23/IL-23R interaction are
known. In this regard, long-term studies with tildrakizumab
will help to address this issue.
In summary, the use of vectors carrying sIL-23R for the
treatment of MS may be a new therapeutic strategy in the
current scenario where most of the current therapies and clin-
ical trials include the use of antibodies or recombinant
proteins. Unfortunately, in the EAE model, a very strong im-
mune response after sensitization with myelin antigen pre-
vents subsequent administration of viral vectors. In order to
study the efficiency of the gene therapy treatment when given
after onset of EAE, sIL-23R constructs carrying inducible
promoters, or the use of different EAE models must be tested.
Moreover, it would be interesting to test the effectiveness of
this strategy in other autoimmune diseases in which the Th17
pathway plays a key role, such as psoriasis, Crohn’s disease or
rheumatoid arthritis.
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